Loading
A phase 3 trial of Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection in non-small-cell lung cancer, run by 3D Medicines (Sichuan) Co., Ltd., now recruiting.
Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC is a phase 3 interventional study registered as NCT06123754 by 3D Medicines (Sichuan) Co., Ltd., with 390 participants planned, started 2023-11-17 and due to reach its primary completion in 2027-12-30. Interventions recorded: Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection and placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection.
Shares 3D Medicines, Envafolimab, Monoclonal antibodies, Immune checkpoint inhibitors and the tag pipeline.
Shares 3D Medicines, Envafolimab, Monoclonal antibodies, Immune checkpoint inhibitors and the tag pipeline.
Shares 3D Medicines, Envafolimab, Monoclonal antibodies, Immune checkpoint inhibitors and the tag pipeline.
Shares Resectable stage I to III non-small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Resectable stage I to III non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Resectable stage I to III non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Resectable stage I to III non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Resectable stage I to III non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.